The two current ongoing Zenith clinical trials are for ZEN-3694 in combo with enzalutamide for metastatic castrate resistant prostate cancer (mCRPC) and for ZEN-3694 in combo with Pfizer's PARP inhibitor Talazoparib in triple-negative breast cancer (TNBC). 

Astrazeneca and Merck recently reported promising Phase 3 results for their PARP inhibitor Lynparza (olaparib) in mCRPC. In their news release, they state that this is the "only PARP inhibitor with positive Phase III results in four different cancer types (ovarian, breast, pancreatic and prostate)." This trial was in mCRPC pateints who "have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone)."

https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019.html

Really seems like Zenith made a great choice going with ZEN-3694 combos with enzalutamide and PARP inhibitors, and for mCPRC and TNBC. If ZEN-3694 proves benefit in TNBC in combo with Pfizer's PARP inhibitor, seems likey that it could also benefit Astrazeneca's PARP inhibitor in both TNBC and mCRPC. Also a nice set up for going after other cancers with HRRm like ovarian and pancreatic cancers.

BDAZ